Key clinical point: Early treatment with lenalidomide may delay disease progression and prevent end-organ damage in patients with high-risk smoldering multiple myeloma (SMM).
Major finding: At 3 years, progression-free survival was 91% in the lenalidomide group and 66% in the observation group (hazard ratio, 0.28; P = .002).
Study details: A phase 3 trial of 182 patients with intermediate- or high-risk SMM.
Disclosures: The trial was funded by the National Cancer Institute. The authors reported financial affiliations with AbbVie, Aduro Biotech, Amgen, Bristol-Myers Squibb, Celgene, Juno Therapeutics, Kite Pharma, Sanofi, Takeda, and several other companies.
Lonial S et al. J Clin Oncol. 2019 Oct 25. doi: 10.1200/JCO.19.01740.